Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over the long term. Key findings: - AxSpA: 3.7% incidence (1.3/100 PY) with BKZ. - PsA: Only 0.2% incidence (0.1/100 PY). - All events were mild/moderate, with no… https://t.co/jkUwHJk3FJ https://t.co/gTcCzeC88e

• https://x.com/i/web/status/1858536895019438208
• https://x.com/synovialjoints/status/1858536895019438208/photo/1

Food for thought 🤔 Abstract 1900 found non-diet soda and certain supplements (folate, B-vitamins, fish oil) were higher among individuals with incident SpA compared to controls @RheumNow #ACR24 https://t.co/qUXcxSfTxE

• https://x.com/AkhilSoodMD/status/1858537901753319481/photo/1

Imaging in TAK Diagnosis @KQuinnRheum @RheumNow ⭐ Take homes ⭐ 👉location of renal artery stenosis (RAS) key to making Dx with proximal RAS in TAK 👉FDG PET -focal uptake in TAK vs diffuse in GCA 👉MRI good surrogate for disease activity where PET unavailable #ACR24 https://t.co/UWxTAZScIt

• https://x.com/DrTrishHarkins/status/1858533026394755568/photo/1
• https://x.com/DrTrishHarkins/status/1858533026394755568/photo/1
• https://x.com/DrTrishHarkins/status/1858533026394755568/photo/1

A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials and long-term extension studies of JAKi and TNFi, in adults with RA, PsO, PsA, axial spondyloarthritis axSpA and IBD showed the following: - TNFi was associated with a significantly… https://t.co/FWHgemEAvG https://t.co/3D0nldwmwA

• https://x.com/i/web/status/1858510483290247578
• https://x.com/synovialjoints/status/1858510483290247578/photo/1

Fantastic interview from @RheumNow from #ACR24 of @DrTrishHarkins talking to @bososhea from @stjamesdublin @tcddublin @TrinityMed1 about carotid doppler ultrasound screening in AxSpA https://t.co/HN1nA5lNTj

• Carotid Doppler Ultrasound Screening in Axial SpA | RheumNow

Rheumatic irAEs can get on the CAR-T bandwagon, too! CAR-T can invoke new rheumatological issues (not just cytokine release) - see @DrGomezPuerta's experience. Infrequent, but if CAR-T in general becomes common, yet another job for us to attend to... #ACR24 ABST2004 @RheumNow https://t.co/xBSlhUdkNr

• https://x.com/drdavidliew/status/1858485108338291164/photo/1

Phase 2 RCT of MK2 inhibitor did not show clinical efficacy at week 12 in active AS pts compared to PBO. There are still unmet needs for additional therapeutics in pts with AS that not respond to current therapies. Abst#1760 #ACR24 @RheumNow https://t.co/cXv8HYr0Xr

• https://x.com/AdelaCastro222/status/1858263006217400826/photo/1
• https://x.com/AdelaCastro222/status/1858263006217400826/photo/1

SURPASS trial of bio naïve axSpA at risk of radiographic progression: 1. Presence of syndesmophytes 2. Higher CRP levels 3. Higher ASDAS 4. Higher spinal MRI BME scores Were predictors of spinal progression independent of ttnt Abst#1759 #ACR24 @RheumNow https://t.co/QC9FMPufPY

• https://x.com/AdelaCastro222/status/1858257553966141559/photo/1
• https://x.com/AdelaCastro222/status/1858257553966141559/photo/1

Dr. BDinneen et al reported predictors that can help screen axSpA pts w/o traditional CV RFs for carotid doppler utz: - shorter dse duration - no family hx of IHD - HLAB27+ - ⬆️ dBP, WHratio, ferritin, TC, LDL and TC:HDL ratio Small size, more data reqd @RheumNow #ACR24 abs1440 https://t.co/3pZxFmutJz

• https://x.com/RHEUMarampa/status/1858257932665659735/photo/1
• https://x.com/RHEUMarampa/status/1858257932665659735/photo/1

The odds of axSpA patients developing fractures was lower among those on TNFi vs DMaRDs or NSAIDs accdg to this study by NGeorge et al. axSpA pts are at high risk of fractures & drugs that mitigate these risks are important. More robust data are needed @RheumNow #ACR24 abs1439 https://t.co/ZSV3og5N5x

• https://x.com/RHEUMarampa/status/1858252752427626764/photo/1